BioCentury
ARTICLE | Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

Ping An Capital leads series C round for cross-border cancer in-licensing play

November 7, 2020 2:38 AM UTC

Apollomics has shored up its Asian investor base with a $124 million series C round that provides the oncology company with flexibility to advance its pair of lead compounds while continuing to hunt for new assets to in-license.

Ping An Capital led the round, which attracted about 10 undisclosed Asia-based investors, only two of which were existing backers of Apollomics Inc., CFO Wilson Cheung told BioCentury...

BCIQ Company Profiles

Apollomics Inc.